DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) is a clinical and commercial stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. The company’s leading product candidate, VAL-083, is a first-in-class small molecule chemotherapeutic that is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Previously, the drug candidate has been the subject of extensive research by the U.S. National Cancer Institute, and it is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China.
In June, DelMar presented an update on its phase I/II clinical trial of VAL-083, and the initial results provide a promising outlook for the company. Despite having failed prior treatment with standard front-line options and having a growing GBM tumor at the time of enrollment in the DelMar clinical trial, 59 percent of patients treated with VAL-083 recorded better than average survival rates. With proper dosing, an improved median overall survival of about nine months was achieved, which marked a meaningful survival benefit over currently available treatment options.
“The overall survival demonstrated at the higher doses in our clinical trial with only two cycles of treatment is clinically meaningful in comparison to published outcomes in this patient population,” Jeffrey Bacha, president and chief executive officer of DelMar, stated in a news release. “We consider these results to be positive and supportive of the further development of VAL-083 as a potential new therapy for GBM patients who have failed other available treatments.”
In the months to come, DelMar will initiate activities to prepare for advancement to registration-directed phase II/III clinical trials of VAL-083. As the company approaches the eventual commercialization of its drug candidate, early results indicate that it could have the potential to replace temozolomide as the standard of care in newly-diagnosed GBM patients whose tumors express features correlated with resistance to standard chemotherapy.
The potential market for DelMar’s drug candidate upon commercialization with the United States is expansive. According to the American Brain Tumor Association, nearly 700,000 people in the U.S. are currently living with a brain tumor, and nearly 70,000 new cases are diagnosed each year. Among these cases, approximately 17 percent are related to GBM. By providing an improved therapeutic option to temozolomide-resistant GBM, the company is in a strong position to promote sustainable growth moving forward.
For prospective shareholders, DelMar’s continued progress toward the domestic commercialization of VAL-083 makes the company an intriguing investment option in the coming months.
For more information, visit www.delmarpharma.com